SignalFDA/Bio

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

Azetukalner NDA submission to FDA for focal seizures plus psychiatry program update.

What changed

Azetukalner NDA submission to FDA for focal seizures plus psychiatry program update.

Why it matters

Azetukalner NDA submission to FDA for focal seizures plus psychiatry program update. — impact context not separately stored; see What changed.

Sources